Skip to main content
Go to homepage

ADVL1411 Temozolomide in Children with Refractory or Recurrent Malignancies

Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies

Description:

This study being completed in collaboration with Cincinnati Children's Hospital. For complete information please visit clinicaltrials.gov

Study Status:
Closed
IRB Study ID:
141003
If you are interested in this study or have questions about your child's eligibility, please contact:
Rebecca D. Considine Research Institute, 330-543-3193 or email research@akronchildrens.org
Lead Investigator
Steven Kuerbitz, MD

Director, Divisional Research, Stem Cell Transplantation & Shannon E. Wilkes Targeted Therapy Program; The Jeffrey A. Barbour Chair for Pediatric Hematology Oncology Research and Healing; Pediatric Hematologist-Oncologist
Showers Family Center for Childhood Cancer and Blood DisordersPediatric Stem Cell Transplant Program